Aimed Alliance’s Director of Public Policy, Stacey L. Worthy, was featured in a Pink Sheet Daily article that discussed how the Institute for Clinical and Economic Review’s (ICER) pricing models limit patient access to life-saving treatments for serious diseases, such as multiple myeloma. The so-called “value frameworks” used by ICER treat patients as commodities and “you can’t put a price-tag on a human life,” said Ms. Worthy. She also added that ICER’s proposals ignore long-term value and constitute a “take-it-or-leave-it” approach, requiring pharmaceutical companies to lower their prices or be wholly excluded from the market. Additionally, Ms. Worthy explained how ICER’s price controls are similar to those employed by the UK’s National Institute for Health and Care Excellence, which has left England a decade behind other countries in Europe in terms of cancer survival rates. The Pink Sheet Daily is a subscription-only news source, but click here to check out their homepage.
Last Updated on May 12, 2020 by Aimed Alliance
